HHS Launches NIH Clinic to Investigate Vaccine Injuries Amidst Growing Concerns

What Happened

The Department of Health and Human Services (HHS) has launched a clinic dedicated to studying patients who have experienced health problems following vaccination.

The new office, located within the National Institutes of Health's (NIH) headquarters in Bethesda, opened earlier this week, according to HHS.

HHS Secretary Robert F. Kennedy Jr. announced the initiative, which includes a research program at the NIH Clinical Center and a new billing code to reimburse doctors for filing reports of serious vaccine side effects.

Kennedy met with several vaccine-injured patients at the NIH headquarters to hear their testimonies and address the Department's intent to prioritize the study of vaccine injuries.

What the Evidence Establishes

A study published in November 2025 found that vaccine injury is significantly underreported, with significant discrepancies in reports regarding adverse events following immunization (AEFIs).

The study, available on the NIH-run PubMed Central, found that underreporting of AEFIs is an issue that requires attention from both the scientific community and public health authorities.

The NIH has published two documents related to vaccine safety on its website, including 'Epidemiological Studies of Vaccination and Health Outcomes Across the Lifespan' and 'Using Clinical Studies and Human-Based Models to Understand Vaccine Mechanisms Impacting Efficacy and Safety'.

These documents suggest that the NIH is taking a more proactive approach to studying vaccine safety and addressing concerns about vaccine injuries.

Where the Accounts Conflict

There are conflicting reports about the number of COVID-19 vaccine-related deaths in children, with some sources suggesting that the FDA may have downplayed autopsy reports.

According to FDA documents released by Republican Wisconsin Sen. Ron Johnson, the FDA may have spun the number of reported COVID-19 vaccine-related deaths in children.

However, the FDA has not commented on these allegations, and it is unclear what the exact number of vaccine-related deaths in children is.

The controversy surrounding vaccine safety has led to increased scrutiny of the FDA and its handling of vaccine-related adverse events.

Context and Stakes

The launch of the NIH clinic to study vaccine injuries marks a significant shift in the government's approach to vaccine safety.

The initiative comes amidst growing concerns about vaccine safety and the need for more rigorous standards for vaccines.

The stakes are high, with the potential for vaccine injuries to have serious consequences for individuals and public health.

The NIH clinic will play a critical role in investigating vaccine injuries and developing strategies to prevent them.

The initiative also has implications for the pharmaceutical industry, with companies like Pfizer and Moderna facing increased scrutiny over their vaccine safety protocols.

What to Watch Next

The NIH clinic's research program will be closely watched, as it has the potential to provide new insights into vaccine safety and the causes of vaccine injuries.

The implementation of the new billing code to reimburse doctors for filing reports of serious vaccine side effects will also be closely monitored.

The FDA's handling of vaccine-related adverse events will continue to be scrutinized, particularly in light of allegations that the agency may have downplayed autopsy reports.

The pharmaceutical industry's response to the initiative will also be important, as companies may need to adapt their vaccine safety protocols to meet new standards.

Bottom Line

The launch of the NIH clinic to study vaccine injuries marks a significant step forward in addressing concerns about vaccine safety.

The initiative has the potential to provide new insights into vaccine injuries and develop strategies to prevent them.

However, the controversy surrounding vaccine safety is likely to continue, and the NIH clinic's research program will be closely watched.

The stakes are high, and the outcome of the initiative will have important implications for individuals, public health, and the pharmaceutical industry.